Autologous T Reg Cell Therapy for Multiple Sclerosis Remission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for relapsing-remitting multiple sclerosis (MS) are plagued by side effects, high costs, and the need for prolonged use, with existing drugs often causing hypercorticism syndrome, depression of bone marrow hemopoiesis, flu-like symptoms, and the risk of progressive multifocal leukoencephalopathy.
Innovation Solution
Administering autologous, ex vivo-expanded CD4+CD25+Foxp3+CD27low regulatory T (T reg) cells during the remission phase to lower autoimmune activity, thereby reducing symptoms and maintaining remission for longer periods without the adverse effects associated with conventional treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoids and immunosuppressive drugs are used for symptomatic treatment, then acute symptoms are reduced, but prolonged use causes hypercorticism syndrome, psychiatric disorders, arterial hypertension, and hypertrichosis
Solution Approach 1:
The patent extracts and administers specifically the regulatory T cells (CD4+CD25+Foxp3+) that mediate immune suppression, separating this beneficial function from the harmful side effects of conventional immunosuppressive drugs. This targeted cell therapy achieves immunomodulation without the systemic toxicity of glucocorticoids and cytostatics.
Solution Approach 2:
The patent uses regulatory T cells as an intermediary biological agent to mediate immune suppression. These cells act as natural mediators that suppress autoreactive T cells and modulate immune responses, providing a physiological mechanism for symptom control without the harsh effects of chemical immunosuppressants.
2Reliability
If cytostatics are used for progressive multiple sclerosis, then disease progression is slowed, but bone marrow hemopoiesis is depressed and tolerability is poor
Solution Approach 1:
The patent extracts and expands regulatory T cells ex vivo to achieve immunosuppression without using cytostatic drugs. This approach selectively targets pathological immune responses while preserving normal bone marrow function, avoiding the myelosuppression caused by conventional cytostatics.
Solution Approach 2:
The patent uses the patient's own regulatory T cells (autologous therapy) to provide immunosuppression. The body's natural regulatory mechanisms are enhanced rather than suppressed by external chemicals, allowing disease control without the toxic side effects of bone marrow depression.
3Reliability
If interferon beta is used for pathogenetic treatment, then antigen presentation is inhibited and inflammatory cells are suppressed, but treatment must continue for at least six months and lifelong, and neutralizing antibodies are produced
Solution Approach 1:
The patent performs preliminary expansion of regulatory T cells ex vivo before administration, creating a high concentration of therapeutic cells that can exert immediate and sustained effects. This preliminary preparation allows for longer-lasting therapeutic action compared to continuous interferon beta administration.
Solution Approach 2:
The patent extracts and concentrates regulatory T cells to deliver a potent, sustained immunomodulatory effect in fewer administrations. This targeted cell therapy achieves prolonged disease control without the need for lifelong continuous treatment required by interferon beta.
4Reliability
If interferon beta is used for treatment, then inflammatory response is reduced, but flu-like symptoms occur including elevated body temperature, acute muscle and joint pain, weakness, and fatigue
Solution Approach 1:
The patent uses regulatory T cells as a biological intermediary to suppress inflammation through physiological mechanisms. These cells naturally modulate immune responses without triggering the flu-like side effects associated with interferon beta administration.
Solution Approach 2:
The patent employs the patient's own regulatory T cells to provide anti-inflammatory effects through the body's natural immune regulation mechanisms, avoiding the foreign protein-induced flu-like symptoms caused by interferon beta therapy.
5Reliability
If conventional treatments are used, then symptomatic relief is achieved, but the cost of treatment is high
Solution Approach 1:
The patent extracts and uses the patient's own cells for therapy, eliminating the need for continuous purchase of expensive pharmaceutical agents like interferon beta. The ex vivo expansion of a limited number of cells provides sustained therapeutic effect, reducing long-term treatment costs.
Solution Approach 2:
The patent replaces expensive, lifelong pharmaceutical treatment with a more cost-effective cell therapy approach. The ex vivo-expanded regulatory T cells provide prolonged therapeutic action, reducing the need for continuous expensive drug administration.
Data Source
AI summary
Disclosed is a method for treating relapsing-remitting multiple sclerosis in a patient by administering to the patient autologous, ex vivo-expanded CD4+CD25+Foxp3+CD127low T reg cells when the patient is in remission. Also disclosed is a method of inhibiting the activity of autoimmune, autologous cytotoxic T and B cells in a patient suffering from relapsing-remitting multiple sclerosis, comprising administering a therapeutically effective amount of autologous CD4+CD25+Foxp3+CD127low T reg cells to the patient.